ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on July 24, 2018 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders dated June 12, 2018 and are available on the
ICON plc website.
The final results of the voting are as follows:
RESOLUTIONNUMBER
RESOLUTION
TOTALNUMBER
OFVOTES
VOTE FOR
VOTEAGAINST
VOTEWITHHELD
1.1
To re-elect Mr. Ciaran Murray
46,363,577 43,309,546 3,049,154 4,877
1.2 To re-elect Mr.
Declan McKeon 46,363,577 45,438,950 919,871 4,756
1.3
To re-elect Mr. EugeneMcCague
46,363,577 46,158,700 200,090 4,787
1.4 To re-elect Ms. Joan
Garahy 46,363,577 46,160,214 198,360 5,003
2
To review the Company'saffairs and
consider theaccounts and reports
46,363,577 46,233,943 1,906 127,728
3
To authorise the fixing of theauditors’
remuneration
46,363,577 43,981,210 2,377,642 4,725
4
To authorise the Company toallot
shares
46,363,577 45,518,647 831,568 13,362
5** To disapply
pre-emption rights 46,363,577 46,218,055 126,968 18,554
6**
To disapply pre-emption rightsfor funding
capital investmentor acquisitions
46,363,577 46,159,710 186,608 17,259
7**
To authorise the Company tomake market
purchases ofshares
46,363,577 45,717,396 461,062 185,119
8**
To authorise the price range atwhich the
Company canreissue shares it holds astreasury shares
46,363,577 46,253,806 97,134 12,637
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 93 locations in 37 countries and has approximately
13,650 employees. Further information is available at
www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180725005262/en/
ICON plcInvestor Relations1 888 381 7923orBrendan BrennanChief
Financial Officer+ 353 1 291 2000Jonathan CurtainVice President
Corporate Finance and Investor Relations+1 215 616 3000
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024